Cardiovascular Implications of Semaglutide in Obesity Management: Redefining Cardiovascular Health Strategies.

Autor:	Binu, Aditya John, Kapoor, Nitin
Předmět:	CARDIOVASCULAR disease prevention PREVENTION of obesity GLUCAGON-like peptide-1 agonists WEIGHT loss GLYCOSYLATED hemoglobin GLYCEMIC control MAJOR adverse cardiovascular events HYPOGLYCEMIC agents CARDIOVASCULAR diseases risk factors DRUG approval TYPE 2 diabetes
Zdroj:	Heart International; 2024, Vol. 18 Issue 1, p3-4, 2p
Abstrakt:	Semaglutide is a glucagon-like peptide 1 receptor agonist that has been noted to have a significant role in the reduction of body weight and glycaemic control. An increasing body of evidence from recent trials (SUSTAIN-6, SELECT and STEP HF) has shown significant cardiovascular benefits of semaglutide in both patients with and without diabetes and in people who are obese or overweight. Additional studies in a more diverse patient population and safety assessment are warranted prior to adding semaglutide to the increasing pool of guideline-directed medical therapy for the treatment and prevention of cardiac diseases. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu